Grand Pharmaceutical

Grand Pharmaceutical (English name: Grand Pharmaceutical Group Limited) is a technology-driven international pharmaceutical enterprise integrating pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, precise interventional diagnosis and treatment for cardiovascular and cerebrovascular diseases, and biotechnology.
Currently, the company has over 10,000 employees globally, more than 30 domestic and overseas subsidiaries, 5 technology platforms and 8 R&D centers. It offers over 200 products listed in the medical insurance catalog and 16 products with sales exceeding 100 million yuan. Its business covers cardiovascular and cerebrovascular diseases, ENT, respiratory and critical care, APIs, mRNA platforms, nuclear medicine anti-tumor diagnosis and treatment, precise interventional diagnosis and treatment for cardiovascular and cerebrovascular diseases, and high-quality amino acids, among other sectors.
Grand Pharmaceutical consistently upholds the corporate spirit of "Dare to be first, share success" and adheres to the business philosophy of "Provide good products, cultivate high standards."
Centered on meeting patient needs, oriented towards adapting to market development, and driven by persistent technological innovation, Grand Pharmaceutical has in recent years strategically invested in a series of innovative pharmaceutical and device products from countries such as the United States, Australia, Germany, and Belgium. It has established in-depth collaborations with top-tier pharmaceutical companies, universities, and research institutions, and has achieved a rich and diversified product pipeline across various cutting-edge medical treatment fields.